Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3106340 | 0.87 | PTGS2 (0.53) | ALDH1A1MAPTGAALMNAKDM4E | |
| SCHEMBL7173488 | 0.75 | ALDH1A1 (0.66) | ALDH1A1MAPTGAALMNAKDM4E | |
| SCHEMBL3106332 | 0.72 | ALDH1A1 (0.54) | ALDH1A1MAPTGAAKDM4ETDP1 | |
| SCHEMBL3554810 | 0.70 | GPBAR1 (0.72) | ALDH1A1MAPTGAALMNAKDM4E | |
| SCHEMBL3106329 | 0.70 | ALDH1A1 (0.56) | ALDH1A1MAPTGAALMNAKDM4E | |
| SCHEMBL8722346 | 0.68 | ALDH1A1 (0.75) | ALDH1A1MAPTGAALMNAKDM4E | |
| SCHEMBL316185 | 0.68 | ALDH1A1 (0.76) | ALDH1A1MAPTGAALMNAKDM4E | |
| SCHEMBL8722344 | 0.67 | TSHR (0.73) | ALDH1A1MAPTGAALMNAKDM4E | |
| SCHEMBL1225498 | 0.67 | PTGS2 (0.67) | ALDH1A1MAPTGAALMNAKDM4E | |
| SCHEMBL1224858 | 0.67 | ALDH1A1 (1.00) | ALDH1A1MAPTGAALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193177-B2 | Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases | ANGION BIOMEDICA CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100256117-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | ANGION BIOMEDICA CORP. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256117-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | HGF, HDGF, HGFAC | ALDH1A1 1992/4885MAPT 4274/4885GAA 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.